Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)
A Randomized, Placebo-Controlled, Double-Blind Study of the Use of Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP Study)
Sponsor: GlaxoSmithKline
A NA clinical study on Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, this trial is ongoing. The trial is conducted by GlaxoSmithKline and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status NA
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status NA
First recorded
Jan 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Urology of Virginia
For direct contact, visit the study record on ClinicalTrials.gov .